Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc., formerly known as Aurasense Therapeutics, is a pioneering biotechnology company that is redefining the landscape of immunomodulatory and gene silencing drugs. Leveraging its proprietary 3-dimensional Spherical Nucleic Acid (SNA™) architecture, Exicure is unlocking the therapeutic potential of nucleic acids across multiple organs. The company focuses on developing treatments targeting validated pathways for conditions ranging from inflammatory disorders to oncology.
Exicure's innovative SNA constructs are designed to overcome one of the most significant challenges in nucleic acid therapeutics: the efficient and safe delivery of therapeutic agents into cells and tissues. These constructs offer unparalleled transfection efficiency into various cell and tissue types, including skin, without the need for carriers or transfection agents. Additionally, SNA constructs hold promise as potent immunotherapeutic agents for addressing cancer and infectious diseases.
At the forefront of Exicure's pipeline are treatments for neurological disorders and hair loss, targeting ribonucleic acid (RNA) against validated disease targets. The company operates in a single segment focused on the discovery, research, and development of SNA-based treatments.
Recent milestones for Exicure include advancements in its lead programs, successful preclinical results, and strategic partnerships aimed at accelerating the development and commercialization of its groundbreaking therapies. These achievements underscore the company's commitment to transforming the future of medicine through cutting-edge nucleic acid technology.
The latest news and updates about Exicure, Inc. highlight the company's ongoing progress and significant developments in the biotechnology sector, providing valuable insights for investors and stakeholders.
Exicure, Inc. (Nasdaq: XCUR) reported its Q3 2022 financial results, revealing a cash position of $16.8 million, down from $48.3 million in 2021. The company generated $2.0 million in revenue, a significant recovery from a net loss of $(3.7) million in the same quarter last year, primarily due to increased collaboration revenue. However, R&D expenses decreased to $4.8 million from $16.5 million, reflecting ongoing strategic cuts. As of September 30, 2022, the firm faces serious doubts regarding the ability to continue operations without additional financing, raising concerns of potential bankruptcy.
Exicure (NASDAQ: XCUR) has announced significant restructuring plans, including a 66% workforce reduction and cessation of all R&D activities. These changes aim to extend cash runway into Q2 2023. Additionally, CBI USA, Inc. intends to purchase 3.4 million shares for $5.4 million, potentially granting them a controlling stake of approximately 50.4%. The company will also explore asset divestiture for its SCN9A program following unsatisfactory clinical trial results.
Exicure, Inc. (NASDAQ: XCUR) announced that CEO Matthias Schroff will present at the 2022 Chardan Genetic Medicines Conference on October 3-4, 2022. The presentation will be available on-demand starting October 3 at 4:00 PM EST for 120 days. Exicure will also conduct one-on-one investor meetings with registered attendees. The company focuses on developing nucleic acid therapies targeting RNA for neurological and hair loss disorders, supported by a skilled team and a dedicated research facility in Chicago.
Exicure, Inc. (Nasdaq: XCUR) reported its Q2 2022 financial results, revealing a revenue of $2.5 million, up from $0.1 million in Q2 2021. The increase was driven by non-cash revenue from collaborations with Ipsen and AbbVie. Despite a net loss of $7.5 million, reduced from $14.3 million a year earlier, the company faces substantial doubt regarding its ability to continue operations without additional financing. The cash position decreased to $23.4 million from $48.3 million at the end of 2021, necessitating further funding to support its SCN9A preclinical program and other initiatives.
Exicure, Inc. (Nasdaq: XCUR) announced on July 19, 2022, that it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The Office of General Counsel confirmed that the company meets all listing standards, leading to the cancellation of a scheduled hearing before the Nasdaq Hearings Panel. Exicure focuses on developing nucleic acid therapies for neurological disorders and hair loss, operating from its Chicago facility.
Exicure, Inc. (NASDAQ: XCUR) announced a one-for-thirty reverse stock split effective today at 5:00 p.m. EDT. This action aims to comply with Nasdaq's minimum bid price requirement of $1.00 per share. Following the split, XCUR's stock will trade on a split-adjusted basis starting tomorrow, June 30, 2022. The company was notified on December 30, 2021, about failing to meet the bid price requirement and was granted a 180-day compliance period, which it did not meet, leading to a potential delisting. The company plans to request a hearing to remain listed on Nasdaq.
Exicure, Inc. (NASDAQ: XCUR) recently held its Annual Meeting of Stockholders on May 27, 2022, which was adjourned without conducting business, rescheduled for June 10, 2022. Key proposals for the reconvened meeting include the election of two directors, ratification of KPMG LLP as independent auditors for the fiscal year ending December 31, 2022, and approval of a proposed reverse stock split at a ratio of 1-for-10 to 1-for-30. The Board believes the reverse stock split is essential for compliance with Nasdaq’s bid price requirement.
Exicure, Inc. (NASDAQ: XCUR) announced that CEO Matthias Schroff will present virtually at the H.C. Wainwright Global Life Sciences Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24, 2022, at 7:00 AM EST and archived for 90 days. The company focuses on developing next-generation nucleic acid therapies aimed at addressing neurological disorders and hair loss. Exicure also plans to conduct one-on-one investor meetings during the conference.
Exicure, Inc. (NASDAQ: XCUR) recently secured a $5.0 million private placement led by CBI USA, aimed at advancing its nucleic acid therapies for neurological and hair loss disorders. The company reported a revenue increase to $2.6 million for Q1 2022, up from $1.0 million in Q1 2021, due to recognition of non-cash revenue from its collaboration with Ipsen. Despite the progress, Exicure faces a net loss of $8.3 million and significant cash flow concerns, raising doubts about its ability to continue operations without additional financing.
Exicure, Inc. (NASDAQ:XCUR) announced a private placement of 26,021,111 shares at $0.1937 per share, totaling approximately $5 million. This financing aims to advance Exicure's preclinical candidates, particularly the SCN9A product for non-opioid pain relief. CBI USA, a subsidiary of CBI Co., Ltd., leads the placement, with closing expected around May 19, 2022. CBI will nominate a board member post-closing. The funds will support the advancement of nucleic acid therapies and general corporate needs.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
What does Exicure, Inc. specialize in?
What are the key areas of focus for Exicure's treatments?
What makes Exicure's SNA constructs unique?
What are some recent achievements of Exicure, Inc.?
How does Exicure contribute to cancer and infectious disease treatment?
What is the primary technology used by Exicure, Inc.?
What segment does Exicure operate in?
How does Exicure ensure the safe delivery of nucleic acid therapeutics?
What are the target diseases for Exicure's lead programs?
Where can I find the latest news about Exicure, Inc.?
